Cayman Fb23-2; 5 Mg; 2243736-45-8; ≥98%

NG 25 is a type II kinase inhibitor that inhibits MAP4K2 and TAK1 (IC₅₀s = 21.7 and 149 nM, respectively). It also inhibits the Src family kinases Src and LYN (IC₅₀s = 113 and 12.9 nM, respectively) and Abl family kinases (IC₅₀s = 75.2 nM), as well as CSK, FER, and p38α (IC₅₀s = 56.4, 82.3, and 102 nM, respectively). NG 25 (100 nM) prevents TNF-α-induced IKKα/β phosphorylation and IκB-α degradation in L929 cells. It inhibits secretion of IFN-α and IFN-β induced by CpG type B and CL097, respectively, in Gen2.2 cells in a concentration-dependent manner. NG 25 decreases cell viability of HCT116^KRASWT, and to a greater degree of HCT116^KRASG13D, colorectal cancer cells in a concentration-dependent manner. It also reduces tumor growth and increases the number of TUNEL-positive tumor cells in a CT26^KRASG12D mouse orthotopic model of colorectal cancer.

WARNING This product is not for human or veterinary use.